Cangene enters marketing and distribution agreement with BioGeneriX AG
Cangene's recombinant human growth hormone ("rhGH") is identical in sequence to naturally-produced human growth hormone of pituitary origin and is manufactured in the Company's new biotechnology manufacturing facility in Winnipeg, Manitoba. Cangene's rhGH is one of the leading products in Cangene's generic biopharmaceutical pipeline and has been tested for use in children with growth hormone deficiency and girls with Turner Syndrome. One of Cangene's core business strategies is to develop generic versions of recombinant proteins using proprietary technology.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.